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Abstract Medical product development (MPD) process
is highly multidisciplinary in nature, which increases the
complexity and the associated risks. Managing the risks
during MPD process is very crucial. The objective of this
research is to explore risks during MPD in a dental product
manufacturing company and propose a model for risk
mitigation during MPD process to minimize failure events.
A case study approach is employed. The existing MPD
process is mapped with five phases of the customized phase
gate process. The activities during each phase of devel-
opment and risks associated with each activity are identi-
fied and categorized based on the source of occurrence.
The risks are analyzed using traditional Failure mode and
effect analysis (FMEA) and fuzzy FMEA. The results of
two methods when compared show that fuzzy approach
avoids the duplication of RPNs and helps more to convert
cognition of experts into information to get values of risk
factors. The critical, moderate, low level and negligible
risks are identified based on criticality; risk treatments and
mitigation model are proposed. During initial phases of
MPD, the risks are less severe, but as the process pro-
gresses the severity of risks goes on increasing. The MPD
process should be critically designed and simulated to
minimize the number of risk events and their severity. To
successfully develop the products/devices within the
manufacturing companies, the process risk management is
very essential. A systematic approach to manage risks
during MPD process will lead to the development of
medical products with expected quality and reliability. This
is the first research of its kind having focus on MPD pro-
cess risks and its management. The methodology adopted
in this paper will help the developers, managers and re-
searchers to have a competitive edge over the other com-
panies by managing the risks during the development
process.
Keywords Risk management  MPD process  FMEA 
Fuzzy theory  RPNs  Case study
Introduction
Medical devices are special products that are directly re-
lated to patient’s health and lives (Lin et al. 2014).
Bringing a new medical product successfully from the
bench to beside is highly complex and depends heavily on
the implementation of rigorous processes. These processes
need to allow developers to optimally phase development,
testing, and other activities, and to successfully execute on
the manifold requirements of third parties, including
regulators and payers. These additional requirements set
medical product/device development apart from the de-
velopment of other products (Pietzsch et al. 2009).
According to I.S. EN ISO 14971 (2012), medical device
means any instrument, apparatus, implement, machine,
appliance, in vitro reagent or calibrator, software, implant,
reagent, material or other similar or related article, in-
tended by the manufacturer to be used, alone or in
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combination, for human beings for one or more of the
specific purposes:
• diagnosis, prevention, monitoring, treatment or alle-
viation of disease,
• diagnosis, monitoring, treatment, alleviation of or
compensation for an injury or disability,
• investigation, replacement, modification or support of
the anatomy or of a physiological process or state,
• supporting or sustaining life,
• control or support of conception,
• disinfection or sterilization of any of the above-
mentioned devices,
• providing information for medical purposes by means
of in vitro examination of specimens derived from the
human body, and which does not achieve its principal
intended action by pharmacological, immunological or
metabolic means in or on the human body; but which
may be assisted in its function by such means.
Medical device classification
North American Industry Classification System (NAICS)
has classified the medical devices industry that is covered
by the Office of Health and Consumer Goods (OHCG) as
illustrated in Fig. 1.
USFDA did analysis based on the data available with
them and interviews conducted with the thought leaders. It
reported that medical device companies lack expertise in
developing risk assessment and mitigation plans during the
product development phases. This significantly impairs
their ability to monitor and control quality through the
manufacturing and the post-production phases. Risk
assessment tools like design and process failure mode and
effects analysis (FMEAs) are often not developed, applied
appropriately (Understanding Barriers to Medical Device
Quality, FDA report, Oct. 31, 2011).
Failure mode and effect analysis (FMEA) is the com-
monly used technique in RM of medical products/devices.
It has got several drawbacks; this paper uses fuzzy FMEA
to compare results with traditional FMEA for RM in MPD
process. However, FMEA and ISO 14971 approaches are
rarely carried out in an integrated manner, either in theory
or in practice. Risk analysis and failure analysis in industry
lack guidance as well as showcase (Chan et al. 2012). In
particular, FMEA is often implemented to improve device
reliability and quality, as well as to correct potential
problems (with an intention to satisfy the ISO9000 and
QS9000 requirements), while ISO 14971 is a mandatory
requirement for the medical devices manufacturer (Chan
et al. 2012). This paper discusses case study of MPD
process. The objectives of study are:
• to get an insight into MPD process,
• to map the existing MPD process of the case under
consideration into customized phase gate process,
• to identify risks during five phases of MPD and
categorize them based on source of occurrence,
Medical 
Devices 
Dental equipment and supplies 
Equipment, instruments, and supplies used by dentists, dental hygienists, and laboratories. 
Specific devices include dental hand instruments, plaster, drills, amalgams, cements, 
sterilizers and dental chairs
Electro medical equipments 
MRI machines, diagnostic imaging equipment and ultrasonic scanning devices.
Dental laboratories 
Crowns, dentures, bridges and other orthodontic devices
Irradiation apparatus  
X-ray devices, other diagnostic imaging, computed tomography (CT) equipment 
Surgical and medical instruments 
Anesthesia apparatus, orthopedic instruments, optical diagnostic apparatus, blood transfusion 
device, syringes, hypodermic needles, and catheters
Surgical appliances and supplies 
Artificial joints and limbs, stents, orthopedic appliances, surgical dressings, disposable 
surgical drapes, hydrotherapy appliances, surgical kits, rubber medical and surgical gloves, 
and wheelchairs
Ophthalmic goods 
Eyeglass frames, lenses and related optical and magnification devices
In- vitro diagnostic substances (IVDs) 
Substances used for diagnostics tests performed in test tubes, Petri dishes, machines, and 
other diagnostic test-type devices.
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• to prioritize the risks using traditional FMEA and fuzzy
FMEA,
• to compare results of traditional FMEA and fuzzy
FMEA,
• to categorize risks based on criticality and propose a
risk mitigation plan.
This paper is further organized as follows: section two
reviews the literature. Section three details the research
methodology adopted. Phase-wise risk identification,
ranking and analysis using traditional FMEA and fuzzy
FMEA are discussed in section four. Section five presents
risk treatments and risk mitigation model. Results, dis-
cussion, conclusion and future scope are discussed in sec-
tion six.
Literature review
This paper discusses a case of MPD process risk identifi-
cation, analysis and management in detail. Different au-
thors have carried research work related to risks in other
PD and MPD which are discussed here.
Product development process risks
As compared to MPD risks, risks in other PD have been
studied more.
Chalupnik et al. (2009) focused on the approaches which
aimed to mitigate the likely impact of process risks on
product performance without removing the sources of
risks. Browning et al. (2002) specified that the goal of PD
process is to produce a recipe that satisfies requirements.
They developed a risk value method to integrate ap-
proaches as technical performance measure tracking charts
and risk reduction profiles. Unger and Eppinger (2011)
discussed PD processes and proposed PD process design
method. The risk categories and steps for risk management
also have been discussed. Zhang and Chu (2011) applied
fuzzy Risk priority number (RPN)-based method to ensure
the robustness against uncertainty of a new horizontal di-
rectional drilling machine. They mentioned that risk ana-
lysis is very important in reducing the failures. Tang et al.
(2011) developed a risk management framework and ap-
plied it to assess customer perception risk in NPD process.
Choi and Ahn (2010) proposed a risk analysis model to
determine the risk degrees of the risk factors occurring in
PD process. They used both fuzzy theory and Markov
processes on concurrent engineering basis. Kayis et al.
(2006) developed a user interactive, dynamic risk man-
agement software package which was commercialized and
deployed successfully by a major international manufac-
turer. Thunnissen (2003) classified the risks and uncer-
tainties in detail. Kayis et al. (2007) identified and
quantified the most prominent risks in the product life
cycle. They also developed five algorithms for finding the
feasible solution for mitigation of the risks. Cooper (2003)
presented a practitioner view of the desired characteristics
of tools to support NPD and suggested a need to construct a
robust risk management framework. The details of the
literature reviewed are as shown in Table 1.
Medical product development risks
A small fault or mistake made in our daily life might not be
so severe but in the health care domain, the smallest mis-
take in development can make the difference between life
and death (Lindholm and Host 2009). ISO 14971 is
dedicated for RM of medical devices, while United States
Food and drug administration (USFDA) strongly implies
the link in their quality system regulation. It is a complete
guide for RM consisting of several steps. There is sparse-
ness of literature on the development process RM of
medical products.
Details of the research related to risks in medical
products are given in Table 2.
It is recommended that, RM should be done through PD
process (ISO 14971:2012; Schmland 2005).
Table 1 Details of the
literature referred
Time period Search engines and journal database used Keywords
1990–2013 Google scholar Medical product
Springer link Medical product development
Science direct Medical device
ASME Medical device development
Inderscience Dental product





J Ind Eng Int (2015) 11:595–611 597
123
Materials and methods
This paper has employed a descriptive method, i.e., a case
study for research as explained by Yin (1984). The objective
of this study is to identify risks during different stages of
development of a dental product, i.e., dental cement. The case
study method has been selected because for this type of re-
search, direct access to the operational and technical decision
makers of the company is required. This facilitates the col-
lection of data through the product developers of the com-
pany. The flow of the research work is depicted in Fig. 2.
History
The case under study has been conducted with a dental
manufacturing company who is into existence for more
than 10 years. It manufactures total sixteen dental prod-
ucts. The company falls under the category of small and
medium sized manufacturing enterprises (SMEs) which are
under tremendous pressure due to free market economy,
rapid technological development and continuous change in
customer demands (Islam and Tedford 2012). In addition to
these, medical product manufacturing companies have to
fulfill the regulatory requirements.
The product
The dental cement falls under the category of dental
equipment and supplies as per NAICS classification (refer
Fig. 1). It is used as a temporary filling to aid recovery of
an inflamed pulp. It acts as a protective base beneath the
amalgamation restoration. For temporary application, it is
used as luting agent for crowns of different materials.
Data collection
Two methods are used for data collection:
1. Interviews with the development team.
2. Referring the documents such as—technical reports,
minutes of meeting, etc.
Analysis
The detailed analysis of the product under study was car-
ried out. Following points were noted during discussion
and the document references:
1. This product was under development since the past
8 months.
2. There were complaints by the end users regarding the
performance, hence modifications were undertaken.
It was been regarded as a good candidate to consider as
a case to identify important risks during MPD process.
The development team consisted of:
• The managing director of the company.
• Two dentists.
• Two manufacturing engineers.
The existing product development process was studied
and is depicted in Fig. 3.
The company was not using any specific model for the
development of the product. Probably the same thing what
many small and medium medical product manufacturing
companies do?
Process mapping
The next part of theworkwas to prepare the development team
for identification of risks during different phases of MPD.
With detailed understanding of the current development pro-
cess (refer Fig. 3), it was mapped with a five phase process.
Medical product development phases and risk
management
Five phases of MPD are considered (Pietzsch et al. 2009).
Lindholm and Host (2009) identified risks using controlled
experiments for procurement of medical product. Cagliano
et al. (2011) used risk breakdown structure to identify risk
sources. This paper identifies the risks involved in MPD
process through the expertise of development team
Table 2 Details of research related to medical product risks
Risk management process attribute Event/case References
Residual risk – Schmland (2005)
Risk analysis Dental implant Braceras et al. (2008)




Medical device failure modes, mechanisms and effect analysis (FMMEA) to identify root
causes and effect mechanisms
Infusion pump failure Cheng et al. (2011)
Risk analysis (ISO 14971) and failure analysis (FMEA) to assure device quality in the design
phase of MPD
Ventilation breathing circuit Chan et al. (2012)
Risk assessment using FMEA and fuzzy linguistic theory Human reliability assessment of
medical devices
Lin et al. (2014)
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{Table 7}                                                                                              {Fig. 4, Table 8}
{Table 7}                                                                                                 {Eq.1,  Table 9, 11} 
{Table 10} 
{Eqs. (2)-(9), Table12} 
{Eqs. (10)-(13)}
{Eq. (14), Table 13}
          {Table13} 
Risk identification through 
Prioritization of risks by five team members using- 
Interviews and brainstorming with development team Access to documents
Mapping of development process with stage gate process 




Identification of critical risks
Risk treatment and mitigation strategy for each risk
Criteria used for selection of case company 
Medical product manufacturing company 
Small/ medium company 
Private limited company 
In house product development(PD)
Research findings and conclusion
Traditional FMEA 
Assign O, S, and D         
to the identified risks 
Calculate RPN for each 
risk (RPN = O*S*D) 
Fuzzy FMEA 
Define fuzzy linguistic variables and 
terms for O, S and D 
Aggregate FMEA team members’ 
individual opinions 
Calculate RPND for each risk 
Determine O, S and D using fuzzy 
linguistic variables 
Determine the weights of each expert 
on a scale of 1. Determine experts’ 
importance of each risk by using 
linguistic terms 
Evaluation of O, S and D by experts 
for all risks using fuzzy linguistics 
Comparison of results of traditional FMEA and fuzzy FMEA
Fig. 2 Methodology used for research
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members. The activities at each stage and the associated
risks are identified as shown in Table 3 along with the risks
identified during each stage.
The risk identification is the most important phase of
this work. A total of twenty most prevalent risks during five
phases of MPD are identified. These risks are classified into
three categories: technical, strategy and market risks. This
categorization is done based on the expert’s opinion, source
of risks and the literature referred (refer Table 4). These
categories contribute individually and interactively to the
product performance (Mu et al. 2009).
The three categories are described as:
1. Technical risks: the risk of not meeting technical and
functional performance requirements, it occurs be-
cause of technical uncertainty.
2. Strategy risks: the risks due to operating strategy of the
company and are mostly associated with culture and
structure of the company.
3. Market risks: even in the absence of risks due to
technology when the device fails to satisfy customer
needs, it is regarded to as market risk.
Table 5 shows the classification of the risks into three
categories and the coding.
It can be seen from Table 5 that the technical risks
contribute most to the MPD process, followed by strategy
risks and market risks, respectively. This research uses two
approaches for risks analysis and prioritization: traditional
FMEA and fuzzy FMEA, which are discussed in detail in
the next subsections.
Failure mode and effect analysis (FMEA)
FMEA is a risk assessment tool to evaluate and mitigate the
potential failures in systems, processes, designs or services
(Lin et al. 2014). It is an effective quality improvement and
risk assessment tool (Tay and Lim 2008) widely used in
practice (Islam and Tedford 2012). FMEA and ISO 14971
risk analysis receive most attention from manufacturing
companies (Chan et al. 2012); therefore, FMEA is used as a
prevention and improvement tool to analyze the risks in
MPD process. The risk during each stage and the associated
consequences related to its occurrence were discussed with
Fig. 3 Existing process of
MPD
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the development team. Calculation of RPNs for identified
risks as prescribed by ISO 14971 (2012) guidelines for risk
analysis is one noticeable step in FMEA to prioritize the
failure modes (Li and Zeng 2014). RPNs are determined by
evaluation of three factors: occurrence (O), severity (S) and
detection (D) (Zhang and Chu 2011) as discussed here:
• Occurrence (O)
The number of times the risk occurs is called as prob-
ability of occurrence.
• Severity (S)
The effect of each risk on the process is expressed in
terms of severity or the level of risk.
• Detection (D)
This ranks the ability of planned tests and inspections to
remove defects or detect failure modes in time. The as-
signed detection number measures the risk that the failure
will escape detection. A high detection number indicates
that the chances are high that the failure will escape de-
tection or, in other words, that the chances of detection are
low.
The three risk factors are evaluated using 10-point
scale as described in Table 6. Risks with higher RPN
values are assumed to be more important and are given
higher priorities over others (Mariajayaprakash et al.
2013). Each potential risk associated with the MPD
process is scored in relation to O, S and D (refer
Table 7).
The methodology of FMEA is shown in Fig. 2.
Table 3 Activities and risks during the phases of medical product development process
Sr. no. Phase Activities Risks
1 Concept Capturing customer requirements Ambiguity in capturing the customer requirements
Finding alternative concepts Lack of modeling the captured requirements
Screening for regulatory strategy Poor evaluation of the requirements in detail
Screening for tooling and fixtures Poor evaluation
2 Architecture Formation of core team Lack of decomposition of the tasks involved
Preparing time schedule Poor selection of methods to accomplish the tasks
Supplier selection and planning Mapping of available resources with the required
Preparing validation plan Poor selection of team members
3 Development Deciding design inputs Poor design specifications
Planning for manufacturing Lack of planning for manufacturing resources
Regulatory strategy Poor quality requirements definition
Clinical validation studies Poor validation strategies
Preparing prototypes
4 Testing Prototype evaluation Wrong selection of design performance parameters
Product risk analysis Poor risk management plans
Finalizing process parameters Discontinued clinical testing
Continued clinical testing Lack of process qualification criteria
5 Validation and launch Validation of product Poor product branding and launching strategy
Product launching Lack of continuous training to product users
Training to dentist/users Lack of post-launch quality audits
Feedback for improvement Discontinued clinical validation
Quality audits
Continued clinical validation
Table 4 Technical and market risks addressed by researchers
Sr. no. Risk category References
1 Technical risk Mikkelsen (1990), Smith (1999); Browning et al. (2002), Saari (2004);
Kayis et al. (2007), Unger and Eppinger (2009) and Unger and
Eppinger (2011)
2 Market risk Thunnissen(2003), Saari (2004), Unger and Eppinger (2009), Unger
and Eppinger (2011), Meherjerdi and Dehghenbaghi (2013) and
Song et al.(2013)
J Ind Eng Int (2015) 11:595–611 601
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Then, RPN is calculated by multiplying O, S and D. The
higher the RPN for a particular factor, the greater is the risk
of failure of the process due to that factor.
Based on RPNs, the risks are ranked as shown in
Table 7. In spite of extensive use of FMEA for risk ana-
lysis, it has been criticized for number of reasons as dis-
cussed here:
1. RPN is calculated by multiplication of O, S and D.
Different combinations of O, S and D have different
risk impacts but may produce same value of RPN. This
may lead to wastage on the part of resources or time.
2. O, S and D have different relative importance which is
not considered in FMEA. The three factors are assumed
to be equally important (Vencheh et al. 2013). This may
not be always the case in practical situation.
3. Precise evaluation of O, S and D is difficult (Liu et al.
2013).
4. The occurrence (O) score is required to be rated and
updated manually from time to time by users based on
their knowledge, experience and with reference to the
latest data. It makes FMEA tedious and time consum-
ing (Tay and Lim 2008).
5. RPNs are not continuous with many holes (Liu
et al.2013).
6. Effectiveness of risk mitigation measures taken cannot
be evaluated using RPN.
In addition to these, authors experienced few other is-
sues with traditional FMEA. The experience of experts is
not considered while calculating RPNs, which is very im-
portant in MPD process where the data regarding O, S and
D are based on the FMEA team members’ experience. Also
asking the experts to assign scores ranging from 1 to 10 for
different risks considered may produce false and unrealistic
impression (Kumru and Kumru 2013). To overcome the
Table 5 Risks coding and
categorization based on source
of occurrence
Sr. no. Risk category Risk code Risk under each category
1 Technical risks T1 Lack of modeling the captured requirements
T2 Poor design specifications
T3 Lack of planning for manufacturing resources
T4 Poor definition of quality requirements
T5 Wrong selection of design performance parameters
T6 Poor risk management plans
T7 Discontinued clinical testing
T8 Lack of process qualification criteria
T9 Poor validation strategies
2 Strategy risks S1 Poor evaluation of the requirements in detail
S2 Poor evaluation of the intellectual resources available
S3 Lack of decomposition of the tasks involved
S4 Poor selection of methods to accomplish the tasks
S5 Mapping of available resources with the required
S6 Poor selection of team members
S7 Lack of post-launch quality audits
S8 Discontinued clinical validation
3 Market risks M1 Ambiguity in capturing the customer requirements
M2 Poor product branding and launching strategy
M3 Lack of continuous training to product users
Table 6 Criteria for the probability of occurrence, severity and detection
Score Occurrence Severity Detection
1 Very unlikely to occur Very low—will not affect the process Certain—fault will be caught on test
2/3 Unlikely to occur Low—may affect the process High
4/5 May occur about half of the time Medium—slightly affect the process Moderate
6/7/8 Likely to occur High—mostly affect the process Low
9/10 Very likely to occur Very high—definitely affect the process Fault will be passed to customer undetected
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drawbacks associated with traditional RPNs, this paper
uses fuzzy approach discussed in the next subsection.
Fuzzy FMEA
Fuzzy linguistic theory has been widely used to solve fuzzy
phenomenon problems existing in the real world, such as
uncertain, imprecise, unspecific and fuzzy situations. It is a
powerful tool for incorporating imprecise data and fuzzy
expressions into decision framework (Liu et al. 2014).
In FMEA, O, S and D are three major risk factors
considered. Under many practical situations, it is difficult
to obtain exact assessment values of the risk factors due to
inherent vagueness and uncertainty in human judgments
(Liu et al. 2014). Hence, fuzzy approach for FMEA has
wide applicability (Liu et al. 2013).
The majority of the fuzzy FMEA approaches use fuzzy
if–then rules to prioritize failure modes, which demand a
rule base of a very large size based on experts’ judgments.
Asking an expert to make so many judgments is practically
unrealistic. The case considered here is subjective and
undefined; the use of fuzzy linguistic is more appropriate.
As such, in this research, the linguistic scale with triangular
fuzzy numbers (TFNs) is used for the evaluation of O, S
Table 7 O, S, D and RPNs for the risks identified by traditional FMEA
Risks (failure modes)
T1 T2 T3 T4 T5 T6 T7 T8 T9 S1 S2 S3 S4 S5 S6 S7 S8 M1 M2 M3
Risk factors
O 5 6 4 7 3 7 9 7 5 5 4 4 6 7 6 6 7 7 5 4
S 2 9 4 7 7 7 4 6 5 3 3 5 6 6 3 6 7 8 7 5
D 2 8 5 5 7 6 6 6 7 2 3 2 4 2 2 6 7 3 8 7
RPN 20 432 80 245 147 294 216 252 175 30 36 40 144 84 36 252 343 168 280 140
Risk ranks 18 1 14 6 10 3 7 5 8 17 16 15 11 13 16 5 2 9 4 12
Table 8 Fuzzy linguistics for O, S, D and corresponding fuzzy numbers
Risk factors Fuzzy linguistic terms
Occurrence VL (very low) L (low) M (medium) H (high) VH (very high)
Severity N (none) Sl (slight) Md (moderate) HS (high severity) VHS (very high severity)













0, 0, 1.5 1, 2.5, 4 3.5, 5, 6.5 6, 7.5 ,9 8.5, 10, 10
Fig. 4 Fuzzy linguistic scale
for O, S and D for MPD process
risks (Lin et al. 2013)
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and D (Fig. 4). The description of linguistic and corre-
sponding fuzzy numbers is shown in Table 8.
The fuzzy O, S and D are based on experience and
expertise of team members. The weights of experts are
calculated using Eq. (1) as different experts have different
influence on the results (Lin et al. 2014).
wtmk ¼ EtmkPn
k¼1 Etmk
; k ¼ 1; 2; 3. . .; n ð1Þ
where tmk and E are kth team member and its expertise,
respectively. The weights of five expert team members are
shown in Table 9.
The result of the evaluation of O, S and D of the 20 risks
identified during MPD process using fuzzy linguistic terms
by five FMEA team members (TM) is shown in Table 10.
Weight of the importance of each risk has been assigned
by experts using fuzzy linguistic terms: unimportant (U),
less important (L), medium important (M), important
(I) and very important (VI) with corresponding fuzzy
numbers (0, 0, 0.15), (0.1, 0.25, 0.4), (0.35, 0.5, 0.65), (0.6,
0.75, 0.9), (0.85, 1, 1), respectively (Fig. 5) (Lin et al.
2013).
Based on experts’ opinions, weight of importance of





ij be the occurrence, severity and de-
tection, respectively, which are evaluated by n experts for




ij 2 T be the member-
ship function for triangular fuzzy number, Wnij be the im-
portance weight evaluated by n respondents for interface i
and risk j, Wnij 2 S be the membership function for it
Onij ¼ OLnij;OMnij;OUnij
 
; Onij 2 T ; where
0OLnijOMnijOUnij 10
ð2Þ
Snij ¼ SLnij; SMnij; SUnij
 
; Snij 2 T ; where









; Wnij 2 S; where
0WLnijWMnijWUnij 1
ð5Þ
Oij ¼ O1ij Wtm1 þ O2ij Wtm2 þ    þ Onij Wtmn ð6Þ
Sij ¼ S1ij Wtm1 þ S2ij Wtm2 þ    þ Snij Wtmn ð7Þ
Table 9 Weights of experts
Experts TM1 TM2 TM3 TM4 TM5
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Table 11 Weight of importance of each risk assigned by team members
FMEA team member Risks
T1 T2 T3 T4 T5 T6 T7 T8 T9 S1 S2 S3 S4 S5 S6 S7 S8 M1 M2 M3
TM1 (0.3) I VI M VI VI VI I M VI L L L M L L M VI I I L
TM2 (0.15) M VI L VI I I M L I L L L L L M I I M I L
TM3 (0.25) VI VI I VI VI VI I M I L L L M M I M I M I M
TM4 (0.15) I VI M I I I I L I M L L L M L M I I I M
TM5 (0.15) I VI M I VI VI VI L M L L L M L M M VI I I L
Table 12 Aggregated fuzzy
information for twenty risks
O S D W
OLj OMj OUj SLj SMj SUj DLj DMj DUj WLj WMj WUj
T1 3.125 4.625 6.125 1.375 2.875 4.375 1.75 3.25 4.75 0.625 0.775 0.8875
T2 3.5 5 6.5 7.75 9.25 9.7 6 7.5 9 0.85 1 1
T3 2.75 4.25 5.75 2.125 3.625 5.125 2.75 4.25 5.75 0.375 0.525 0.675
T4 6 7.5 9 2.75 4.25 5.75 2.5 4 5.5 0.775 0.925 0.97
T5 3.5 5 6.5 6 7.5 9 5.25 6.75 8.25 0.775 0.925 0.97
T6 6.375 7.875 9.15 6 7.5 9 5 6.5 8 0.775 0.925 0.97
T7 7.125 8.625 9.45 2 3.5 5 3.875 5.375 6.875 0.6 0.75 0.8775
T8 5 6.5 8 5.25 6.75 8.25 4.25 5.75 7.25 0.2375 0.3875 0.5375
T9 3.125 4.625 6.125 2.75 4.25 5.75 5 6.5 8 0.6375 0.7875 0.8925
S1 2.125 3.625 5.125 1.75 3.25 4.75 0.6 1.5 3 0.1375 0.2875 0.4375
S2 2.75 4.25 5.75 1 2.5 4 2 3.5 5 0.1 0.25 0.4
S3 3.125 4.625 6.125 2.75 4.25 5.75 0.45 1.125 2.625 0.1 0.25 0.4
S4 3.5 5 6.5 2.875 4.375 5.875 1.75 3.25 4.75 0.275 0.425 0.575
S5 4.625 6.125 7.625 6 7.5 9 1 2.5 4 0.2 0.35 0.5
S6 3.875 5.375 6.875 1 2.5 4 0.6 1.5 3 0.3 0.45 0.6
S7 7.5 9 9.6 5.25 6.75 8.25 5.25 6.75 8.25 0.3875 0.5375 0.6875
S8 7.75 9.25 9.7 4.5 6 7.5 6 7.5 9 0.7125 0.8625 0.945
M1 7.375 8.875 9.55 7.75 9.25 9.7 1.75 3.25 4.75 0.5 0.65 0.8
M2 2.5 4 5.5 6.375 7.875 9.15 7 8.5 9.4 0.6 0.75 0.9
M3 2.125 3.625 5.125 2.125 3.625 5.125 6 7.5 9 0.2 0.35 0.5
Fig. 5 Fuzzy linguistic scale
for weight of importance of
each risk (Lin et al. 2013)
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Dij ¼ D1ij Wtm1 þ D2ij Wtm2 þ    þ Dnij Wtmn ð8Þ
Wij ¼W1ijWtm1 þW2ij Wtm2 þ    þWnijWtmn ð9Þ
where Oij; Sij; Dij are occurrence, severity and detection
values of experts’ team members opinion for interface i and
risk j, Wij is importance for each risk evaluated by experts’
team members for interface j and risk ji, Wtmk is the weight
of kth team member and n is the number of experts’ team
members, respectively.
The fuzzy numbers for probability of occurrence (O),
severity (S), detection (D) and fuzzy weights for each risk
by each team member (W) are aggregated based on expert
team members’ subjective opinion using Eqs. (6)–(9) (Lin
et al. 2013). The aggregated fuzzy information for twenty
risks is shown in Table 12.
The values shown in Table 12 for twenty risks in MPD
process are fuzzy sets. Defuzzification of the fuzzy sets is
necessary to convert the fuzzy sets into numerical values.
Table 13 RPND values for all risks
Risk code Risks RPN by traditional
FMEA
Rank RPN by fuzzy FMEA
(RPND)
Rank
T1 Lack of modeling the captured requirements 20 18 32.95132 15
T2 Poor design specifications 432 1 317.0625 3
T3 Lack of planning for manufacturing resources 80 14 34.3752 14
T4 Poor definition of quality requirements 245 6 113.475 9
T5 Wrong selection of design performance parameters 147 10 225.2813 4
T6 Poor risk management plans 294 3 338.4225 1
T7 Discontinued clinical testing 216 7 117.3336 8
T8 Lack of process qualification criteria 252 5 97.75898 11
T9 Poor validation strategies 175 8 98.69895 10
S1 Poor evaluation of the requirements in detail 30 17 5.758086 20
S2 Poor evaluation of the intellectual resources available 36 16 9.296875 18
S3 Lack of decomposition of the tasks involved 40 15 6.879688 19
S4 Poor selection of methods to accomplish the tasks 144 11 30.21484 16
S5 Mapping of available resources with the required 84 13 40.19531 12
S6 Poor selection of team members 36 16 10.27969 17
S7 Lack of post-launch quality audits 252 5 213.0616 5
S8 Discontinued clinical validation 343 2 336.42 2
M1 Ambiguity in capturing the customer requirements 168 9 161.6908 7
M2 Poor product branding and launching strategy 280 4 194.22 6
M3 Lack of continuous training to product users 140 12 34.49414 13
Critical risks (CR): 
RPNs: above 200 
Moderate risks 
(MR): RPNs:  100- 
200 
Low level  risks 
(LR): RPNs:  50-
100 
Negligible  risks 
(NR): RPNs below 
50 
Fig. 6 Risks categorization and comparison based on RPNs using traditional FMEA and fuzzy FMEA
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There are different algorithms for defuzzification, such as
centre of gravity, centre of gravity for singletons, centre of
area, left most maximum, right most maximum (Kumru
and Kumru 2013) and mean of maximum. As compared to
Mean of maximum (MoM), Centre of Area (CoA) yields
better results (Lin et al. 2014). Fuzzy occurrence, severity,
detection and fuzzy weight of importance of each risk in
MPD process have been calculated using Eqs. (10)–(13)
(Lin et al. 2013), respectively.
DOk ¼ ½ OUk  OLkð Þ þ OMk  OLkð Þ
3
þ OLk 8k ð10Þ
DSk ¼ ½ SUk  SLkð Þ þ SMk  SLkð Þ
3
þ SLk 8k ð11Þ
DDk ¼ ½ DUk  DLkð Þ þ DMk  DLkð Þ
3
þ DLk 8k ð12Þ




RPND is calculated using DOk, DSk, DDk and DWk.
RPND ¼ DOk  DSk  DDk  DWk ð14Þ
Table 13 shows the RPND values for all twenty risks
identified during MPD process using Eq. (14) (Lin et al.
2013).
A comparison of RPN by traditional FMEA and RPND
obtained by fuzzy FMEA is shown in Table 13. After do-
ing the comparative analysis of the risks identified during
MPD process using Traditional FMEA and Fuzzy FMEA,
it is found that later has some advantages as compared to
traditional FMEA (Liu et al. 2013):
• Complex and ambiguous data can be handled in a
consistent manner for risk assessment.
• Risk evaluation function can be customized based on
the nature of process.
• Combination of three factors, O, S and D, of risks in
more flexible and realistic way is possible.
At the same time, it has some drawbacks as discussed
here (Liu et al. 2013):
• To define appropriate membership function, risk factor
is a crucial task.
• Any modification in the number of linguistic scale and
terms requires redefinition of membership functions.
• User has to deal with complex calculations to draw the
inferences.
• Even when their membership functions overlap, they
provide arbitrary priority ranks of failure modes
(Mandal and Maiti 2014).
After calculating RPNs using traditional FMEA and
fuzzy FMEA, the risks during MPD process are catego-
rized as: critical risks (CR), moderate risks (MR), low level
risks (LR) and negligible risks (NR) based on the RPNs
calculated and their criticality.
The detailed categorization and comparison of risks are
shown in Fig. 6. The limits of RPNs for categorization are
set based on experts’ opinions.
Mapping risks to the MPD phases
After carrying the detailed analysis of the risks identified,
the risks are mapped back to the five phases of MPD
process. A phase-wise comparison between the results of
traditional FMEA and fuzzy FMEA based on their category
and severity is shown in Fig. 7.
Risk mitigation
The next step in the risk management is to suggest risk
mitigation strategy for the identified risks. As a result of
brainstorming and discussion with the MPD experts, the
risk treatment for each risk and the mitigation strategy for
each category of criticality are recommended as shown in
Table 14.
Concept Architecture Development Tesng Validaon and launch 









CR T2            T4 T2 
T6           
T7           
T8 
T5           
T6 
S7           
S8           
M2 
S7           
S8           
MR M1 M1 S4 T9 T4 T5 T7 M3 M2 
LR S5 T3 T8 T9 
NR 
T1            
S1            
S2 
T1            
S1            
S2            
S3            
S6 
S3            
S4            
S5            
S6  
T3 M3 
Fig. 7 Phase-wise scatter of risks based on category and severity
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Risk mitigation model
A risk mitigation model is developed (Fig. 8) based on the
risks identified and the mitigation strategy suggested. The
model has a logical flow. MPD process risks are shown on
right-hand side of the model. Critical, moderate, low level
and negligible risks are represented in convergent manner
as per the severity of occurrence. The area covered by each
Table 14 Risk treatments and mitigation strategies recommended
Risk
category




T2 poor design Specifications Detailed documentation of the design Prepare and implement risk response
plan immediatelyS8 discontinued clinical
validation
Mention criteria for acceptance of validation
Clinical validation should be continued, the period
for the same should be determined
T6 poor risk management plans Decide the decision making points in risk
management
Decompose the risks into categories and prepare plan
in detail
S7 lack of post-launch quality
audits
The quality audit points should be pre-decided
The criteria for acceptance at each point should be
decided
T8 lack of process qualification
criteria
A clear process qualification criteria should be
specified
T4 poor definition of quality
requirements
The quality at each stage must be clearly defined
M1 ambiguity in capturing the
customer requirements
Clear definition of the customer and end user
Requirements should be grasped in detail
Moderate
risks (MR)
M2 poor product branding and
launching strategy
Experts should be involved to finalize the strategy Take action within a short period of
time to avoid future risks
T7 discontinued clinical testing Clinical testing period should be specified based on
the technicalities involved in product
T9 poor validation strategies Standard strategies and methods should be adapted
for validation
Keep a track and make preventive
action plan
T5 wrong selection of design
performance parameters
Design stages should be pre-defined.
Inputs and expected outcome at each stage should be
specified
Take action within a short period of
time to avoid future risks
M3 lack of continuous training to
product users
Additional user training should be provided Keep a track and make preventive
action plan
S4 poor selection of methods to
accomplish the tasks
Study of appropriate methods and their application is
necessary
Additional training on methods should be provided
Low level
risks (LR)
T3 lack of planning for
manufacturing resources
Manufacturing planning and monitoring should be
done
Keep a track and make preventive
action plan
S3 lack of decomposition of the
tasks involved
Decompose the task logically and categorically Accept the risk actively and take the
corrective action
S2 poor evaluation of the
intellectual resources available
Complete know how of the available intellectual
resources is required
Capabilities of all resources should be known
S6 poor selection of team
members
Based on the stage wise requirements of the product,
the team should be formed
S1 poor evaluation of the
requirements in detail
The actual requirements and their mapping with the
product requirements should be done
S5 mapping of available
resources with the required
All the resources available and required should be
mapped with each other
Negligible
risk (NR)
T1 lack of modeling the captured
requirements
Modeling of the requirements should be done to
optimize the resources and outcomes
Take action if consequences occur
again in future
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risk is proportional to the severity. Common risk mitigation
strategies for risks of different category based on criticality
are shown on left-hand side of the model. Residual risks are
shown in the model, which still remain after applying the
mitigation strategy. The acceptable level of each residual
risk should be calculated and decision may be taken based
on the severity of the residual risk.
Though the model discussed here is specific for the case
considered, it will be useful for any other industry for the
purpose of risk mitigation.
Results and discussion
The risk management methodologies refer to a standard
process presenting the well-known steps: risk identifica-
tion, risk evaluation and quantification, risk mitigation for
treatment and/or impact minimization and risk monitoring
(Marmier et al. 2013). Most of the research on RM has
focused on risk identification and analysis.
A case study of undefined and subjective MPD, i.e.,
dental cement, is presented here. The existing MPD pro-
cess is mapped with the standard phase gate process with
necessary customization. A total of twenty risks are ex-
plored during five phases of the MPD. These risks are
categorized as: technical, strategy and market risks based
on the source of occurrence. RPN for each risk is calcu-
lated using traditional FMEA and fuzzy FMEA; their re-
sults are compared. The risks are further categorized as
critical, moderate, low level and negligible risks based on
their RPN and the criticality. The risks are mapped back to
the five phases of development process to know the sources
and criticality of different risks along each phase.
Traditional FMEA gives 40 % CRs, 20 %MRs,
10 %LRs and 25 %NRs out of total risks (Fig. 9). During
concept phase, 10 % of risks are MRs and 15 % are NRs.
Architecture Phase has 5 % of MR, LR each and 10 %
NRs. Development phase has 10 % CRs, 5 % MR and LR
each. During testing, 15 % are CRs and 5 % MR. Last
phase has 15 % CRs and 5 % MR (Fig. 10).
Fuzzy FMEA resulted in 25 % CRs, 20 % MRs, 10 %
LRs and 45 % NRs out of total risks. Concept phase has
5 % MR and 15 % NRs. Architecture Phase has 20 % NRs;
development phase has 5 % CR, MR and NR each. Testing
has 10 % CRs, 5 % MR and LR each. Validation and
launch have 10 % CRs, 5 % MR, LR and NR each
(Fig. 10). The concept and development phases have more
MRs and NRs as compared to other phases. Results of
prioritizing MPD process risks using fuzzy FMEA are
found to be more logical as compared to traditional FMEA.
It filtered the critical risks from 40 to 25 %, which helps to
deal with CRs, efficiently and effectively.
The study provides a detailed methodology for the de-
velopers, managers and researchers to explore MPD pro-
cess risks and perform risk management using traditional












Fig. 9 Comparison between results of traditional FMEA and fuzzy
FMEA based on criticality of risks
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FMEA and fuzzy FMEA approach. The risks identified
though specific in nature provide a guideline for develop-
ment processes of other medical products and devices. Also
the use of FMEA is discussed in detail. The mitigation
model will serve as a generic model for risk mitigation.
Conclusion and future scope
This paper presented a case of managing risks during MPD
process. It can be concluded from this case study that MPD
process has number of risks, whose management and
mitigation are extremely necessary to reduce failure events
due to process. During initial phases of MPD, the risks are
less severe; but as the process progresses the severity of
risks goes on increasing. The MPD process should be
critically designed and simulated to minimize the number
of risk events and their severity. Considering opinions of
the experts on results, fuzzy FMEA approach gives more
precise, appropriate and logical results as compared to the
traditional FMEA.
The case study research has many advantages and
limitations as well. The risks identified are specific for the
case under consideration. The RPNs calculated, risk pri-
oritization and categorization are also specific, but can be
customized and effectively applied for other cases. The
conclusions drawn are limited for the particular case; hence
more number of such studies needs to be carried in future.
Other techniques for risk analysis should be used and
compared with the results reported here. A detailed survey
of the medical product development companies will be
useful in drawing statistics-based conclusions.
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